1. Effect of intravenous immunoglobulin (IVIg) on primate complement-dependent cytotoxicity of genetically engineered pig cells: relevance to clinical xenotransplantation
- Author
-
Hayato Iwase, Hidetaka Hara, Abhijit Jagdale, Diyan Patel, David Ayares, Yehua Cui, Takayuki Yamamoto, and David K. C. Cooper
- Subjects
0301 basic medicine ,Cytotoxicity, Immunologic ,Primates ,Erythrocytes ,Swine ,Xenotransplantation ,medicine.medical_treatment ,Transplantation, Heterologous ,Heterologous ,lcsh:Medicine ,Drug development ,030230 surgery ,Article ,Animals, Genetically Modified ,03 medical and health sciences ,0302 clinical medicine ,Species Specificity ,hemic and lymphatic diseases ,medicine ,Cytotoxic T cell ,Animals ,Humans ,Cytotoxicity ,lcsh:Science ,Multidisciplinary ,biology ,business.industry ,lcsh:R ,Antibody-Dependent Cell Cytotoxicity ,Immunoglobulins, Intravenous ,Complement System Proteins ,Flow Cytometry ,Complement-dependent cytotoxicity ,Transplantation ,030104 developmental biology ,Immunoglobulin M ,Preclinical research ,Immunoglobulin G ,Immunology ,biology.protein ,lcsh:Q ,Antibody ,business ,Biomarkers ,Allotransplantation ,Papio - Abstract
Triple-knockout (TKO) pigs may be ideal sources of organs for clinical xenotransplantation because many humans have no preformed antibody to TKO pig cells. Intravenous immunoglobulin (IVIg) is widely used for severe infection or the treatment/prevention of antibody-mediated rejection in allotransplantation. Anti-pig antibodies in IVIg could be harmful in clinical xenotransplantation. It is unknown whether anti-TKO pig antibodies are present in IVIg. The main aim of this study was to investigate in vitro whether IVIg contains anti-TKO pig antibodies with cytotoxic effect to pig cells. Undiluted pooled human serum (HS) and five different commercial preparations of IVIg were tested for IgM and IgG binding to red blood cells (RBCs) from wild-type (WT), α1,3-galactosyltransferase gene-knockout (GTKO), and TKO pigs by flow cytometry. Complement-dependent lysis of IVIg against these pig pRBCs was measured by hemolytic assay. Pooled HS and 4 of 5 IVIg commercial preparations contained anti-pig IgG that bound to WT and GTKO pRBCs, but not to TKO pRBCs. One preparation of IVIg contained antibodies that bound to TKO pRBCs, but there was no cytotoxicity of IVIg to TKO pRBCs. The results suggest that IVIg administration to human recipients of TKO pig grafts would be safe. However, the specific preparation of IVIg would need to be screened before its administration.
- Published
- 2020